Tagged Articles

Januvia 202 articles

Merck seeks Japanese approval to market new type 2 diabetes drug

A 12-week study on the new type 2 diabetes treatment omarigliptin is proving effective at reducing blood sugar levels in diabetic patients, according to research published in the journal Diabetes Care. The study is an extension of a longer-term safety and tolerability study of 25 mg dose of omarigliptin over 66 weeks. Researchers found that when patients taking omarigliptin were compared to patients taking metformin, adverse events remained similar, hypoglycemia was rare, and the drug was well tolerated. Merck & Co. has filed a new drug application for omarigliptin in Japan, with plans to file for approval in the United ... Read More

Newer diabetes drugs linked to acute pancreatitis

Diabetics treated with a newer classes of diabetes drugs have double the risk of being hospitalized with acute pancreatitis, according to a study published in JAMA Internal Medicine. The drug class, known as incretin mimetics, which includes the subclass GLP-1 drugs, include the brand names Januvia (sitagliptin) and Byetta (exenatide). Researchers with Johns Hopkins University School of Medicine in Baltimore found that the drugs contribute to the formation of lesions in the pancreas and an increase in the number of ducts within it, which adds to the frequency and severity of inflammation. Drug regulators were aware of this possibility when ... Read More

Newer type 2 diabetes drugs linked to side effects affecting the skin

Newer treatments for type 2 diabetes are proving effective in the management of the disease, but their list of side effects continues to grow as more patients take the drugs over longer periods of time. According to Clinical Endocrinology News, the newer classes of diabetes drugs, which includes DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors, have all been linked to potentially serious adverse effects to the skin. DPP-4 inhibitors, which include the brand names Januvia, Janumet and Tradjenta, have been linked to a condition known as bullous pemphigoid, a rare skin condition that causes large, fluid-filled blisters on areas of ... Read More

People with diabetes pay more for health care

Diabetes makes people more susceptible to several serious health conditions, but the disease can also be a pain in one’s wallet. “The cost of diabetes treatment has been increasing pretty rapidly,” says Glen Stettin, senior vice president for clinical, research and new solutions at Express Scripts. For four years straight, spending on diabetes treatments was higher per person than it was for any other class of traditional drug. Diabetics already pay about $5,000 more annually for their medications than people without the disease, according to a study by the Health Care Cost Institute, which examined insurance claims of nearly 40 ... Read More

FDA warns of severe joint pain with class of type 2 diabetes drugs

People taking a certain class of type 2 diabetes medications known as DPP-4 inhibitors are at risk of joint pain that can become so severe that it can be debilitating, the Food and Drug Administration (FDA) warned. The agency advised patients to not stop taking their diabetes medications and to talk to their doctors right away if they experience any severe and persistent joint pain. The agency has ordered makers of these drugs to update the Warnings and Precautions section on the drugs’ labels, and also notified doctors to be aware of this new side effect. The warnings arose from ... Read More

Diabetes drug maker announces results from cardiovascular study

Type 2 diabetes is a serious disease that increases the risk for life threatening health conditions including heart disease, kidney disease and cancer. Medications can help diabetics manage their blood sugar levels but their side effects can be just as concerning. Many of the newer diabetes treatments have been linked to cardiovascular events or cancer risks. But a new study suggests the diabetes drug Jardiance can help reduce the risk for heart attacks, strokes and other cardiovascular damage. Jardiance contains the active ingredient empagliflozin, and was approved by the FDA in August 2014. It is in a new class of diabetes ... Read More

New side effects added to label of type 2 diabetes drugs Tradjenta, Jentadueto

Type 2 diabetes drugs that contain the active ingredient linagliptin have updated their safety labels to warn that some patients have developed painful mouth ulcers after taking the medication, according to the Food and Drug Administration (FDA). Linagliptin is the active ingredient in the brand-name diabetes treatments Tradjenta and Jentadueto. The drugs are in a newer class of diabetes treatments know as dipeptidyl peptidase-4 inhibitors, or DPP-4. Other drugs in this class include Januvia and Janumet. These medications are in a wider class of drugs known as incretin mimetics, which includes brands such as Byetta and Victoza. Mouth ulcers are ... Read More

People advised to ignore rumors about type 2 diabetes med Januvia

Odd rumors involving the type 2 diabetes drug Januvia swirling around social media are completely bogus, says the Ministry of Health in Dubai. The rumors claim that Januvia is derived from the saliva of monitor lizards and can cure diabetes in just one year. Januvia contains the active ingredient sitagliptin. The medication is a newer type of diabetes treatment but does not include any lizard byproducts, the agency says, adding that people should not believe the advertisements on social media and to check with their doctors before taking any medications that might endanger their lives. Neither Januvia or any other ... Read More

Substantial growth expected in type 2 diabetes treatment market

The global market for type 2 diabetes treatments is expected to increase in value over the next few years from a value of $23.5 billion in 2014 to an estimated $39 billion by 2021, fueled by the increasing number of people developing the disease and the barrage of new brand-name diabetes treatments entering the market. The prediction was made by business intelligence provider GBI Research, which published the report Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2012 – Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth. The company said the increase will occur across the ... Read More

Victoza being tested as a treatment for nonalcoholic fatty liver disease

The type 2 diabetes drug Victoza can help resolve a type of nonalcoholic fatty liver disease in overweight patients, according to a new study presented at the 2015 International Liver Congress. The specific nonalcoholic fatty liver disease is called nonalcoholic steatohepatitis, or NASH. It is a common, often “silent” liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The major feature with NASH is fat in the liver, along with inflammation and damage. Most people are not aware they have a liver problem. However, it can become severe and lead to cirrhosis, ... Read More